These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2431345)

  • 1. Relative affinities for different classes of neurotransmitter receptors predict neuroleptic efficacy in infantile autism: a hypothesis.
    Deutsch SI; Campbell M
    Neuropsychobiology; 1986; 15(3-4):160-4. PubMed ID: 2431345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic binding to human brain receptors: relation to clinical effects.
    Richelson E
    Ann N Y Acad Sci; 1988; 537():435-42. PubMed ID: 2904784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic drugs: prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue.
    Black JL; Richelson E
    Mayo Clin Proc; 1987 May; 62(5):369-72. PubMed ID: 2883343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
    Richelson E
    J Clin Psychiatry; 1984 Aug; 45(8):331-6. PubMed ID: 6146602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuroleptics in geriatrics. Pharmacological criteria for a responsible choice and a correct use].
    van Wielink PS
    Tijdschr Gerontol Geriatr; 1984 Apr; 15(2):73-80. PubMed ID: 6144201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding.
    Peroutka SJ; Snyder SH
    Science; 1980 Oct; 210(4465):88-90. PubMed ID: 6251550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
    Liao Y; Venhuis BJ; Rodenhuis N; Timmerman W; Wikström H; Meier E; Bartoszyk GD; Böttcher H; Seyfried CA; Sundell S
    J Med Chem; 1999 Jun; 42(12):2235-44. PubMed ID: 10377229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency.
    Peroutka SJ; Synder SH
    Am J Psychiatry; 1980 Dec; 137(12):1518-22. PubMed ID: 6108081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacology of neuroleptics: focus on new generation compounds.
    Richelson E
    J Clin Psychiatry; 1996; 57 Suppl 11():4-11. PubMed ID: 8941166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile.
    Glatt CE; Snowman AM; Sibley DR; Snyder SH
    Mol Med; 1995 May; 1(4):398-406. PubMed ID: 8521297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors.
    Bylund DB
    J Pharmacol Exp Ther; 1981 Apr; 217(1):81-6. PubMed ID: 6110776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of neuroleptics in use in the United States.
    Richelson E
    J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):8-14. PubMed ID: 2862140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
    Reitz AB; Bennett DJ; Blum PS; Codd EE; Maryanoff CA; Ortegon ME; Renzi MJ; Scott MK; Shank RP; Vaught JL
    J Med Chem; 1994 Apr; 37(8):1060-2. PubMed ID: 7909336
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigations on the binding properties of the nootropic agent pyroglutamic acid.
    Barone D; Spignoli G
    Drugs Exp Clin Res; 1990; 16(2):85-99. PubMed ID: 1976055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotransmitter-receptor binding in various brain regions in ethanol-dependent rats.
    Hunt WA; Dalton TK
    Pharmacol Biochem Behav; 1981 May; 14(5):733-9. PubMed ID: 6113608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors.
    Nimit Y; Schulze I; Cashaw JL; Ruchirawat S; Davis VE
    J Neurosci Res; 1983; 10(2):175-89. PubMed ID: 6313954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding.
    Dahl SG; Hough E; Hals PA
    Biochem Pharmacol; 1986 Apr; 35(8):1263-9. PubMed ID: 2870716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic agents do not interact with neurotransmitter receptors.
    Peroutka SJ
    Cancer Chemother Pharmacol; 1987; 19(2):131-2. PubMed ID: 3568270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors.
    Muller P; Seeman P
    Life Sci; 1977 Dec; 21(12):1751-8. PubMed ID: 203807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.